Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy

Journal of Viral Hepatitis

Volumn 16, Issue 12, 2009, Pages 867-875

  Arends, J E ^a   Stuart, J Cohen ^b   Baak, L C ^b   Van Der Ende, M E ^c   Van Erpecum, K J ^b   Simons, C P M ^c   Boland, G J ^b   Van Baarle, D ^a   Hoepelman, A I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Medical Microbiology ^*  (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

48 h; First phase; Genotype 1 and 4; Hepatitis C; HIV; Rapid viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PRIORITY JOURNAL; SUSTAINED VIRAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; VIRUS TYPING;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70449359224     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01143.x     Document Type: Article

References (50)

1. Nguyen TT, Sedghi-Vaziri A, Wilkes LB et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996 3 : 75 78.
2. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996 23 : 366 371.
3. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997 26 : 226 231.
4. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 : 103 107.
5. Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998 27 : 1149 1156.
6. Bekkering FC, Brouwer JT, Schalm SW, Elewaut A. Hepatitis C: viral kinetics. Hepatology 1997 26 : 1691 1693.
7. Zeuzem S. The kinetics of hepatitis C virus infection. Clin Liver Dis 2001 5 : 917 930.
8. Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology 2005 42 : 749 754.
9. Olle K, Anders S, Ola W. Similar hepatitis C virus RNA kinetics in HIVhepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy. AIDS 2008 22 : 899 901.
10. Sherman KE, Shire NJ, Rouster SD et al. Viral kinetics in hepatitis C or hepatitis Chuman immunodeficiency virus-infected patients. Gastroenterology 2005 128 : 313 327.
11. Torriani FJ, Ribeiro RM, Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCVHIV coinfection. J Infect Dis 2003 188 : 1498 1507.
12. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003 10 : 271 276.
13. Layden JE, Layden TJ. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 2002 35 : 967 970.
14. Rosen HR, Ribeiro RR, Weinberger L et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002 37 : 124 130.
15. Tang KH, Herrmann E, Cooksley H et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005 43 : 776 782.
16. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002 9 : 340 345.
17. Jessner W, Stauber R, Hackl F et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003 10 : 37 42.
18. Herrmann E, Zeuzem S. The kinetics of hepatitis C virus. Eur J Gastroenterol Hepatol 2006 18 : 339 342.
19. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004 53 : 15 18.
20. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357 : 124 134.
21. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44 : 97 103.
22. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008 48 : S5.
23. National Institute of Health. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002 19 : 1 46.
24. Nelson M, Matthews G. British HIV Association (BHIVA) guidelines for treatment and management of HIV and hepatitis C coinfection, 2004. Available at: http://www.bhiva.org/guidelines/2004/HCV/index html.
25. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005 42 : 615 624.
26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
27. Colombatto P, Civitano L, Oliveri F et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003 8 : 519 530.
28. Herrmann E, Zeuzem S. Hepatitis C viral kinetic models. Cell Death Differ 2003 10 : S7 S8.
29. Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 2006 78 : 446 451.
30. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839 2848.
31. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 : 438 450.
32. Ballesteros AL, Franco S, Fuster D et al. Early HCV dynamics on Peg-interferon and ribavirin in HIVHCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004 18 : 59 66.
33. Núñez M, Miralles C, Berdún MA et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007 23 : 972 982.
34. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003 37 : 1351 1358.
35. Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002 14 : 833 840.
36. Shudo E, Ribeiro RM, Talal AH, Perelson AS. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 2008 13 : 919 926.
37. Schinkel J, Spaan WJ, Kroes AC. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir Ther 2004 9 : 275 286.
38. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007 20 : 23 38.
39. Lau DT, Fish PM, Sinha M, Owen DM, Lemon SM, Gale M Jr. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008 47 : 799 809.
40. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006 69 : 129 141.
41. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003 23 (Suppl. 1 23 28.
42. Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C virus and HIV co-infection. Drugs 2004 64 : 2823 2843.
43. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008 105 : 7034 7039.
44. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007 46 : 1548 1563.
45. Khakoo S, Glue P, Grellier L et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998 46 : 563 570.
46. Pawlotsky JM, Dahari H, Neumann AU et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004 126 : 703 714.
47. Asahina Y, Izumi N, Enomoto N et al. Mutagenic effects of ribavirin and response to interferonribavirin combination therapy in chronic hepatitis C. J Hepatol 2005 43 : 623 629.
48. Barnes E, Harcourt G, Brown D et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002 36 : 743 754.
49. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002 76 : 8505 8517.
50. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004 432 : 922 924.